Both in vivo and in vitro, 4-AAQB significantly targets KRAS-mutated CRC through the induction of miR-193a-3p expression, thus targeting KRAS-mutant CRC tumorigenesis. This evidence concerns the gene KRAS and colorectal carcinoma.